In NCC-expressing HEK293 cells, 1 μM SEA0400 suppressed the calcium signal triggered by high extracellular potassium and prevented NCC dephosphorylation. A SEA0400-insensitive NCX1 mutant preserved potassium-induced NCC dephosphorylation during treatment, supporting NCX1 involvement in this cellular response. [2]
SEA0400 effects depended on NCX expression in isolated mouse ventricular myocytes. It slowed NCX-associated calcium removal in all tested lines. In paced cells, spontaneous calcium releases decreased in NCX-overexpressing cells but increased in cells with normal or reduced NCX expression; the event-count increase in one wild-type line was a nonsignificant trend. Knockout-line cells showed frequent calcium hypercontraction and subsequent cell death. These cellular readouts do not establish whole-heart antiarrhythmic efficacy. [3]
Inhibition of native cardiac NCX current
Cell-based study · Isolated ventricular myocytes from male guinea pigs; whole-cell voltage clamp [1]
SEA0400 inhibited both inward and outward Ni2+-sensitive NCX currents. Potency values are assay endpoints, not treatment doses. KB-R7943 was tested separately as comparator.
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration-response experiment; 1 μM SEA0400 quantified in Results
- Exposure duration
- Drug-exposure duration not specified in text
- Method
- Bath application during ramp voltage clamp at 35–36°C; Ni2+-sensitive current defined using 5 mM Ni2+
- Co-treatment
- No combined inhibitor treatment; KB-R7943 tested separately
- Reported limits
- Vehicle and a fixed SEA0400 equilibration time not specified in the inspected Methods/Results.
Methods and source locations
Compound reported in the paper: SEA0400
Reported SEA0400 material and experimental model only; no product-lot equivalence or human efficacy established.
Methods; Table 1; Results: Effect of SEA0400 and KB-R7943 on NCX current; Figure 1A–E
Inhibition of inward current at −80 mV and outward current at +30 mV: Interpolation between two data points near 50% inhibition; means ± SEM in Figure 1, n = 3–4 experiments, cells from different animals. — Methods; Results: NCX current; Figure 1E
NCX current remaining at 1 μM SEA0400, relative to drug-free current: Mean ± SEM; Figure 1 caption gives n = 3–4 experiments. Not percentages of inhibition. — Results: NCX current; Figure 1A,C,E
Ion-current selectivity within the tested cardiac panel
Cell-based study · Isolated male guinea-pig ventricular myocytes; separate whole-cell recordings for Na+, L-type Ca2+, inward rectifier K+ and delayed rectifier K+ currents [1]
At 1 μM, SEA0400 had no significant effect on the four tested channel currents. At 10 μM, partial reductions in L-type Ca2+ and inward rectifier K+ currents limited concentration-independent selectivity claims.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 μM SEA0400; additional 10 μM SEA0400 channel tests
- Exposure duration
- Fixed exposure time not specified in text
- Method
- Whole-cell voltage clamp; Na+ current at 22–23°C, other currents at 35–36°C
- Co-treatment
- KB-R7943 (10 μM) is a separate comparator, not co-treatment
- Reported limits
- Vehicle and fixed equilibration time not specified in inspected Methods/Results.
Methods and source locations
Compound reported in the paper: SEA0400
Reported SEA0400 material and experimental model only; no product-lot equivalence or human efficacy established.
Methods; Table 1; Results: Effect of SEA0400 and KB-R7943 on ion channel currents; Figures 2–5
Four ionic current amplitudes after 1 μM SEA0400, relative to drug-free current: Mean ± SEM, n = 4 per figure captions; paired t-test. Endpoints at −20 mV, +10 mV, −60 mV, and tail after +50 mV, respectively. — Results: ion channel currents; Figures 2–5
Additional channel responses to 10 μM SEA0400: Mean ± SEM; relative to current in absence of drug. Text-reported values; no unshown graph inferred. — Results: ion channel currents, final paragraph; Discussion
SEA0400 suppresses potassium-evoked calcium signaling and NCC dephosphorylation
Cell-based study · Flp-In NCC HEK293 cells; CaN-B overexpressed for NCC-dephosphorylation experiments unless otherwise stated [2]
At 1 μM, SEA0400 suppressed the high-K+-evoked Fluo-4 response and prevented NCC dephosphorylation. In the specificity-control extension, K+-induced NCC dephosphorylation remained detectable in cells expressing SEA0400-insensitive F213L NCX1 despite SEA0400 treatment.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 μM SEA0400
- Exposure duration
- 1 h pretreatment before K+ stimulation; Fluo-4 image at 30 s after stimulation
- Method
- High-K+ challenge (10 mM final) versus normal K+ (3 mM); Fluo-4 imaging and phospho-NCC/total-NCC immunoblotting
- Co-treatment
- High-K+ stimulus; CaN-B expression in NCC assays; F213L versus wild-type NCX1 specificity control
- Reported limits
- SEA0400 vehicle for cultured-cell experiments and fixed high-K+ incubation duration for Figure 3C are not explicitly specified in its caption; no time borrowed from another figure.
Methods and source locations
Compound reported in the paper: SEA0400
Reported SEA0400 material and experimental model only; no product-lot equivalence or human efficacy established.
Materials and methods: Cell culture and transfections, Intracellular calcium assay, Western blotting; Results: Reverse-mode NCX plays a role in the Ca2+ influx pathway; Figure 3B,C; S8 Figure; S1 File
K+-evoked intracellular calcium signal: Representative imaging at 30 s and time course; no replicate number or inferential statistic specified for Figure 3B. — Figure 3B and caption; Intracellular calcium assay; Results: Reverse-mode NCX
K+-induced change in phosphorylated NCC relative to total NCC: n = 6 per figure caption; mean ± SEM per general statistics; p < 0.05 for indicated normal/high-K+ comparison, Tukey after two-way ANOVA; no exact band ratios inferred. — Figure 3C and caption; S8 Figure and caption; S1 File immunoblot methods
Forward-mode NCX functional readout in genetically distinct myocytes
Cell-based study · Isolated ventricular cardiomyocytes from NCX-overexpressing (OE), heterozygous knockout (hetKO) mice and their respective wild-types; mice <12.5 weeks [3]
SEA0400 increased the time to half-decay of caffeine-induced calcium transients in all four lines, consistent with reduced forward-mode NCX-mediated calcium removal.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 μM SEA0400
- Exposure duration
- Before caffeine: 1 Hz field stimulation for 1 min then 10 s rest; fixed drug-equilibration interval not specified
- Method
- 10 mM caffeine challenge; Fluo-4-AM calcium imaging at room temperature
- Co-treatment
- Caffeine as readout stimulus, not a therapeutic combination
- Reported limits
- Supplier, chemical form, vehicle and fixed drug-equilibration time are not specified in the inspected article.
Methods and source locations
Compound reported in the paper: SEA0400
Reported SEA0400 material and experimental model only; no product-lot equivalence or human efficacy established.
Methods: NCX transgenic mouse models, Ca2+ epifluorescence measurements, Statistics; Results: Effects of SEA0400 on NCX-mediated Ca2+ removal; Figure 1
Time to 50% decay of caffeine-induced Ca2+ transient: Mean ± SEM; n cells/mice basal → drug: OE 37/5 → 21/3; WTOE 42/5 → 25/3; hetKO 26/4 → 24/3; WThetKO 24/4 → 24/3. All drug versus basal p < 0.05, ANOVA on ranks; arrows do not imply a paired sample of identical cells. — Results: Effects of SEA0400 on NCX-mediated Ca2+ removal; Figure 1B,D
NCX-expression-dependent calcium responses and adverse cellular events
Cell-based study · Isolated OE, hetKO, WTOE and WThetKO ventricular cardiomyocytes; mice <12.5 weeks; indo-1-AM imaging [3]
SEA0400 increased stimulated calcium-transient amplitude in wild-types and hetKO, but not OE. It decreased spontaneous release events in OE while increasing events in WThetKO and hetKO; WTOE showed a nonsignificant upward trend in event count. Hypercontraction with subsequent cell death was especially frequent in hetKO.
Literature-Reported Treatment Conditions
- Treatment concentration
- Sequential 0.3 and 1 μM SEA0400; adverse-event results at 1 μM
- Exposure duration
- Each sequence: 1 Hz stimulation for 4 min followed by 20 sweeps at 0.125 Hz; repeated within the same cell after drug addition
- Method
- Indo-1-AM imaging at room temperature; basal/drug comparisons
- Reported limits
- Supplier, chemical form, vehicle and separate equilibration interval are not specified in inspected text.
Methods and source locations
Compound reported in the paper: SEA0400
Reported SEA0400 material and experimental model only; no product-lot equivalence or human efficacy established.
Methods: Ca2+ epifluorescence measurements and Statistics; Results: Ca2+ transient amplitude and spontaneous Ca2+ transients; Figures 2–4; Limitations
Field-stimulated calcium-transient amplitude relative to basal: Steady-state end of 1 Hz pacing; mean ± SEM; repeated-measures ANOVA. At 1 μM n cells/mice: OE 23/8; WTOE 23/7; hetKO 9/3; WThetKO 16/4. Amplitude is a proxy; direct contractility not measured. — Results: Effects of SEA0400 on the Ca2+ transient amplitude; Figure 2
Spontaneous calcium releases per analyzed cell during 0.125 Hz pacing: Mean ± SEM; repeated-measures ANOVA: significant drug changes in OE, WThetKO and hetKO; WTOE upward trend. n cells/mice basal → drug: OE 27/8 → 23/8; WTOE 27/7 → 23/7; WThetKO 19/4 → 16/4; hetKO 19/5 → 8/3. — Results: Influence of SEA0400 on proarrhythmic spontaneous Ca2+ transients; Figure 3B
Cells with abrupt calcium hypercontraction and subsequent cell death during 1 μM SEA0400: hetKO versus WThetKO p < 0.05; OE versus WTOE p > 0.05, Fisher exact test in Results. Only 42% of measured hetKO cells remained analyzable; event-count/amplitude data therefore reflect surviving analyzable cells. No denominator invented. — Results: Influence of SEA0400, final paragraph; Figure 4; Limitations